3Deus Dynamics

3Deus Dynamics, based in France, specializes in advanced 3D printing technologies that produce high-performance silicone parts with unique properties for medical and aerospace applications. Established in 2020 in France, 3Deus Dynamics focuses on innovative 3D printing solutions, particularly for medical devices and aerospace components. The company has successfully raised EUR 3. 7 mn in its latest funding round on December 18, 2025, primarily aimed at supporting product development initiatives.

3Deus Dynamics specializes in advanced 3D printing technologies, focusing on the production of enhanced silicone parts with functional properties such as conductivity, fire resistance, and electromagnetic shielding. Its core offerings include the development of medical devices across all classifications, customizable anatomical models for surgical planning, and fire-resistant components tailored for aerospace applications. These products are characterized by ultra-realistic tactile qualities and biocompatibility, manufactured in facilities certified under the ISO 13485 standard. The company leverages its patented Dynamic Molding process to achieve complex geometries that traditional 3D printing cannot, serving sectors like healthcare, aerospace, and defense with a customer base that includes hospitals and manufacturers across Europe, North America, and Asia.

The revenue model of 3Deus Dynamics is structured around direct business-to-business transactions, primarily involving the sale of customized medical and aerospace components. Clients engage through feasibility studies, co-development agreements, and on-demand manufacturing services for small to medium production runs. The flagship product line includes patented silicone printing solutions that cater to specified market needs in healthcare and aerospace, with pricing plans negotiated based on complexity and customization of models, facilitating ongoing relationships with clients for tailored solutions. In December 2025, 3Deus Dynamics raised EUR 3.

7 mn in venture funding to support its industrialization and product development initiatives. The company plans to introduce new products focused on advanced medical applications and expand into additional markets in North America and Asia, targeting a rollout by late 2026.